The global vaccine contract manufacturing market size was estimated at USD 2.14 billion in 2023 and is expected to reach USD 3.60 billion by 2030, growing at a CAGR of 7.8% from 2024 to 2030. This steady growth reflects the rising global demand for vaccines and the increasing preference among pharmaceutical and biotechnology companies for contract manufacturing models. The growing trend toward contract manufacturing is driven by the need to reduce capital expenditure, improve production flexibility, and accelerate time-to-market for vaccine products, particularly in response to emerging and re-emerging infectious diseases.

Increasing vaccination coverage across both developed and developing regions, along with continuous innovations in vaccine technologies, is expected to act as high-impact growth drivers for the market. The number of vaccines in the clinical development phase is consistently rising, largely due to the proven effectiveness of vaccines in preventing and managing a wide range of infectious and non-infectious diseases. As vaccine demand continues to grow, the requirement for contract manufacturing services is also increasing, as these services help reduce development timelines and support faster commercialization of new vaccine products. Both well-established pharmaceutical companies and emerging biotech firms are increasingly leveraging contract manufacturing organizations (CMOs) and contract research organizations (CROs) as strategic partners to accelerate their vaccine research and development efforts.

Consequently, the increased adoption of contract manufacturing and research services is anticipated to contribute to the development of a robust and diversified vaccine pipeline in the near future. Growing concerns regarding global vaccine shortages and inequitable access to vaccines are among the high-impact factors expected to further expand the scope of the vaccine contract manufacturing market. These challenges are particularly pronounced in emerging economies with limited manufacturing infrastructure and financial resources. As a result, outsourcing vaccine production to specialized CMOs is being increasingly adopted as an effective solution to scale up manufacturing capacity and ensure a more reliable vaccine supply.

With ongoing technological advancements in biologics manufacturing, formulation, and process optimization, the number of companies outsourcing vaccine production to CMOs continues to increase. In response, CMOs are actively expanding their manufacturing facilities, enhancing research and development capabilities, and investing in advanced technologies to meet the growing global demand for vaccines. These developments are strengthening the overall ecosystem of vaccine contract manufacturing and supporting long-term market growth.

Key Market Trends & Insights:

• The vaccine contract manufacturing market in North America accounted for the largest share of the global market, primarily due to the widespread manufacturing of vaccines across the region and the strong presence of a large number of biopharmaceutical manufacturing facilities. Favorable regulatory frameworks, well-established healthcare infrastructure, and significant investments in vaccine development further support regional market dominance. Within North America, the vaccine contract manufacturing market in the U.S. held the largest share, driven by the presence of leading pharmaceutical companies, contract manufacturers, and advanced research institutions.
• Based on vaccine type, the attenuated vaccines segment led the market in 2023, accounting for the largest revenue share of 29.9%. This dominance is attributed to the long-standing use, proven efficacy, and wide application of attenuated vaccines in immunization programs. However, the DNA vaccines segment is expected to witness the fastest CAGR of 9.5% over the forecast period. DNA vaccines are anticipated to offer lucrative growth opportunities in the future due to their potential advantages, including rapid development timelines, stability, and the ability to target a broad range of diseases.
• Based on workflow, the downstream segment dominated the market with the largest revenue share of 50.9% in 2023. This can be attributed to the complexity and critical nature of downstream processes such as purification, formulation, and fill-finish operations, which often require specialized expertise and infrastructure. The upstream segment is expected to witness the fastest CAGR of 8.0% over the forecast period, supported by increasing investments in cell culture technologies, fermentation processes, and scalable production systems.
• Based on application, the human-use segment led the market with the largest revenue share of 92.24% in 2023. The strong demand for human vaccines, driven by national immunization programs, pandemic preparedness initiatives, and increasing awareness of preventive healthcare, continues to support the dominance of this segment.

Order a free sample PDF of the Vaccine Contract Manufacturing Market Intelligence Study, published by Grand View Research.

Market Size & Forecast:

• 2023 Market Size: USD 2.14 Billion
• 2030 Projected Market Size: USD 3.60 Billion
• CAGR (2024-2030): 7.8%
• North America: Largest market in 2023

Key Companies & Market Share Insights:

Key companies operating in the vaccine contract manufacturing market are adopting a range of strategic initiatives, including mergers and acquisitions, collaborations, regional expansions, service portfolio enhancements, and competitive pricing strategies, to strengthen their market presence and gain higher market share in a competitive environment. These strategies enable companies to expand their capabilities, address capacity constraints, and cater to a broader customer base. For instance, in October 2023, Vaxcyte and Lonza announced the expansion of their collaboration for the global commercial manufacturing of broad-spectrum Pneumococcal Conjugate Vaccines (PCVs). This collaboration underscores the growing reliance on experienced contract manufacturers to support large-scale vaccine production and highlights the critical role of strategic partnerships in meeting global vaccine demand efficiently.

Key Players

• Lonza
• FUJIFILM Diosynth Biotechnologies
• Ajinomoto Co., Inc.
• Merck KGaA
• Catalent, Inc
• IDT Biologika GmbH
• Curia Global, Inc.
• ICON plc.
• Cytovance Biologics (Hepalink)
• Syngene International Limited

Explore Horizon Databook – The world's most expansive market intelligence platform developed by Grand View Research.

Conclusion:

In conclusion, the vaccine contract manufacturing market is poised for steady growth, driven by rising global vaccine demand, expanding immunization coverage, and continuous innovation in vaccine development. The increasing reliance on CMOs and CROs enables pharmaceutical companies to accelerate R&D, reduce production timelines, and optimize manufacturing costs. Concerns related to vaccine shortages and unequal access, particularly in emerging economies, further reinforce the need for scalable contract manufacturing solutions. Technological advancements and capacity expansions by CMOs are strengthening the overall manufacturing ecosystem. Collectively, these factors are expected to support the development of a robust vaccine pipeline and sustain long-term market expansion through 2030.